|
Gene: SMTN |
Gene summary for SMTN |
Gene summary. |
Gene information | Species | Human | Gene symbol | SMTN | Gene ID | 6525 |
Gene name | smoothelin | |
Gene Alias | SMTN | |
Cytomap | 22q12.2 | |
Gene Type | protein-coding | GO ID | GO:0003008 | UniProtAcc | A0A087X1R1 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
6525 | SMTN | HTA11_3410_2000001011 | Human | Colorectum | AD | 2.51e-03 | 9.19e-02 | 0.0155 |
6525 | SMTN | HTA11_1391_2000001011 | Human | Colorectum | AD | 1.29e-02 | 4.07e-01 | -0.059 |
6525 | SMTN | HTA11_7696_3000711011 | Human | Colorectum | AD | 1.16e-16 | 5.76e-01 | 0.0674 |
6525 | SMTN | HTA11_99999974143_84620 | Human | Colorectum | MSS | 6.14e-07 | 3.07e-01 | 0.3005 |
6525 | SMTN | A015-C-203 | Human | Colorectum | FAP | 2.68e-03 | 1.36e-01 | -0.1294 |
6525 | SMTN | A002-C-116 | Human | Colorectum | FAP | 5.97e-04 | -1.74e-01 | -0.0452 |
6525 | SMTN | LZE4T | Human | Esophagus | ESCC | 1.24e-08 | 1.90e-01 | 0.0811 |
6525 | SMTN | LZE7T | Human | Esophagus | ESCC | 1.67e-02 | 8.67e-02 | 0.0667 |
6525 | SMTN | LZE20T | Human | Esophagus | ESCC | 4.73e-02 | 5.19e-02 | 0.0662 |
6525 | SMTN | LZE24T | Human | Esophagus | ESCC | 7.56e-08 | 8.76e-02 | 0.0596 |
6525 | SMTN | P1T-E | Human | Esophagus | ESCC | 5.85e-08 | 3.25e-01 | 0.0875 |
6525 | SMTN | P2T-E | Human | Esophagus | ESCC | 6.40e-03 | 3.68e-02 | 0.1177 |
6525 | SMTN | P4T-E | Human | Esophagus | ESCC | 1.49e-07 | 1.95e-01 | 0.1323 |
6525 | SMTN | P5T-E | Human | Esophagus | ESCC | 6.87e-04 | 3.33e-02 | 0.1327 |
6525 | SMTN | P8T-E | Human | Esophagus | ESCC | 6.01e-09 | 4.29e-02 | 0.0889 |
6525 | SMTN | P9T-E | Human | Esophagus | ESCC | 5.73e-10 | 1.50e-01 | 0.1131 |
6525 | SMTN | P10T-E | Human | Esophagus | ESCC | 4.26e-09 | 2.11e-01 | 0.116 |
6525 | SMTN | P11T-E | Human | Esophagus | ESCC | 8.39e-15 | 5.18e-01 | 0.1426 |
6525 | SMTN | P12T-E | Human | Esophagus | ESCC | 4.88e-11 | 1.57e-01 | 0.1122 |
6525 | SMTN | P15T-E | Human | Esophagus | ESCC | 1.11e-05 | 1.68e-01 | 0.1149 |
Page: 1 2 3 4 5 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00030121 | Colorectum | MSS | muscle system process | 105/3467 | 452/18723 | 6.39e-03 | 4.26e-02 | 105 |
GO:00030122 | Colorectum | FAP | muscle system process | 89/2622 | 452/18723 | 4.63e-04 | 5.39e-03 | 89 |
GO:000751716 | Thyroid | ATC | muscle organ development | 139/6293 | 327/18723 | 4.45e-04 | 2.64e-03 | 139 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SMTN | SNV | Missense_Mutation | rs144949047 | c.2972N>A | p.Arg991Gln | p.R991Q | protein_coding | deleterious(0.04) | probably_damaging(0.996) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD | |
SMTN | SNV | Missense_Mutation | rs538229101 | c.2855N>T | p.Ala952Val | p.A952V | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-QS-A744-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Chemotherapy | carboplatin | SD | |
SMTN | deletion | Frame_Shift_Del | rs778461809 | c.1760delN | p.Ser590ValfsTer64 | p.S590Vfs*64 | protein_coding | TCGA-AJ-A3OJ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR | |||
SMTN | deletion | Frame_Shift_Del | rs778461809 | c.1767delC | p.Ser590ValfsTer64 | p.S590Vfs*64 | protein_coding | TCGA-AP-A05O-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | PD | |||
SMTN | deletion | Frame_Shift_Del | rs778461809 | c.1767delC | p.Ser590ValfsTer64 | p.S590Vfs*64 | protein_coding | TCGA-AX-A2HJ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |||
SMTN | deletion | Frame_Shift_Del | rs778461809 | c.1760delN | p.Ser590ValfsTer64 | p.S590Vfs*64 | protein_coding | TCGA-B5-A11H-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Hormone Therapy | megace | SD | |||
SMTN | insertion | Frame_Shift_Ins | novel | c.1411_1412insG | p.Arg473AlafsTer6 | p.R473Afs*6 | protein_coding | TCGA-EO-A3KX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |||
SMTN | deletion | Frame_Shift_Del | rs778461809 | c.1760delN | p.Ser590ValfsTer64 | p.S590Vfs*64 | protein_coding | TCGA-EY-A215-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |||
SMTN | deletion | Frame_Shift_Del | rs778461809 | c.1767delC | p.Ser590ValfsTer64 | p.S590Vfs*64 | protein_coding | TCGA-FI-A2F4-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |||
SMTN | SNV | Missense_Mutation | novel | c.2549A>G | p.Lys850Arg | p.K850R | protein_coding | tolerated(0.05) | probably_damaging(0.995) | TCGA-2Y-A9GS-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
6525 | SMTN | NA | TRANSFORMING GROWTH FACTOR | 12390831 |
Page: 1 |